Pharmacoepidemiology Study to Define the Long-term Safety Profile of Tenofovir Disoproxil Fumarate (Tenofovir DF, Viread) and Describe the Management of Tenofovir DF-associated Renal and Bone Toxicity in Chronic Hepatitis B (CHB)-Infected Adolescents Aged 12 to <18 Years in Europe
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 08 Nov 2017 Planned End Date changed from 1 Jun 2019 to 1 Jan 2018.
- 08 Nov 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Jan 2018.
- 30 Jun 2017 Status changed from recruiting to active, no longer recruiting.